LADENBURG THALM/SH SH reiterated their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Thursday, reports. LADENBURG THALM/SH SH currently has a $3.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the company. Mizuho cut their target price on Marinus Pharmaceuticals from $5.00 to $1.70 and set a neutral rating on the stock in a research note on Tuesday, July 23rd. ValuEngine upgraded Worldline from a hold rating to a buy rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald reissued a buy rating and set a $60.00 price target on shares of Benefitfocus in a report on Wednesday, May 1st. Finally, Zacks Investment Research raised HB Fuller from a sell rating to a hold rating in a report on Wednesday, July 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. Marinus Pharmaceuticals presently has a consensus rating of Hold and an average price target of $11.39.

MRNS stock traded down $0.08 during mid-day trading on Thursday, reaching $1.12. The company had a trading volume of 1,826,868 shares, compared to its average volume of 1,639,790. Marinus Pharmaceuticals has a one year low of $0.77 and a one year high of $10.54. The business has a 50-day moving average price of $3.95.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03). Analysts predict that Marinus Pharmaceuticals will post -0.94 EPS for the current fiscal year.

In other news, CFO Edward F. Smith sold 24,211 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $5.03, for a total transaction of $121,781.33. Following the transaction, the chief financial officer now directly owns 20,097 shares of the company’s stock, valued at $101,087.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.10% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of MRNS. Millennium Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 76.4% during the fourth quarter. Millennium Management LLC now owns 315,842 shares of the biopharmaceutical company’s stock valued at $906,000 after purchasing an additional 136,830 shares during the period. Geode Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 34.7% during the fourth quarter. Geode Capital Management LLC now owns 464,483 shares of the biopharmaceutical company’s stock worth $1,332,000 after acquiring an additional 119,668 shares during the period. Two Sigma Advisers LP acquired a new position in Marinus Pharmaceuticals during the fourth quarter worth about $146,000. Bailard Inc. acquired a new position in Marinus Pharmaceuticals during the first quarter worth about $138,000. Finally, Squarepoint Ops LLC acquired a new position in Marinus Pharmaceuticals during the fourth quarter worth about $69,000. 63.35% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Read More: Why is the Consumer Price Index (CPI) important?

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with's FREE daily email newsletter.